ClinicalTrials.gov
ClinicalTrials.gov Menu

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03756818
Recruitment Status : Not yet recruiting
First Posted : November 28, 2018
Last Update Posted : November 28, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This phase I trial studies the best dose and side effects of TAK-659 and paclitaxel in treating patients with advanced solid tumors. TAK-659 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving TAK-659 and paclitaxel may work better in treating patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Malignant Solid Neoplasm KRAS Gene Mutation Ovarian Carcinoma Refractory Malignant Solid Neoplasm Refractory Ovarian Carcinoma Drug: Paclitaxel Other: Pharmacokinetic Study Drug: Spleen Tyrosine Kinase Inhibitor TAK-659 Phase 1

Detailed Description:

PRIMARY OBJECTIVES I. To define the maximum tolerated doses (MTD) of spleen tyrosine kinase inhibitor TAK-659 (TAK-659) and paclitaxel.

II. To define the safety profiles of the combination.

SECONDARY OBJECTIVES I. To evaluate clinical response signals to the combination. II. To analyze pharmacokinetic interactions between TAK-659 and paclitaxel. III. To assess predictive biomarkers (baseline molecular mutation status) and/or resistant pathways by comparing molecular signatures at baseline versus at time of relapse in patients who have achieved objective responses.

OUTLINE: This is a dose-escalation study of spleen tyrosine kinase inhibitor TAK-659 and paclitaxel.

Patients receive spleen tyrosine kinase inhibitor TAK-659 orally (PO) once daily (QD) and paclitaxel intravenously (IV) over approximately 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 28 days.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of TAK-659 and Paclitaxel in Patients With Advanced Solid Tumors
Estimated Study Start Date : December 31, 2018
Estimated Primary Completion Date : February 24, 2022
Estimated Study Completion Date : February 24, 2022


Arm Intervention/treatment
Experimental: Treatment (TAK-659 and paclitaxel)
Patients receive spleen tyrosine kinase inhibitor TAK-659 PO QD and paclitaxel IV over approximately 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Paclitaxel
Given IV
Other Names:
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol
  • Taxol Konzentrat

Other: Pharmacokinetic Study
Correlative studies
Other Names:
  • PHARMACOKINETIC
  • PK Study

Drug: Spleen Tyrosine Kinase Inhibitor TAK-659
Given PO
Other Names:
  • Spleen Tyrosine Kinase Inhibitor TAK659
  • syk Inhibitor TAK-659
  • syk Inhibitor TAK659
  • syk-Inhibitor TAK-659
  • syk-Inhibitor TAK659
  • TAK-659
  • TAK659




Primary Outcome Measures :
  1. Incidence of adverse events and serious adverse events assessed by NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 5.0 [ Time Frame: Up to 4 years ]
    Adverse events (clinical manifestations and laboratory tests) and serious adverse events will be assessed by clinical symptoms and laboratory values, evaluation of vital signs, and performance of physical exam with a special attention to treatment-related fatigue, gastrointestinal symptoms, cardiovascular events, myelosuppression, and neurotoxicity.

  2. Incidence and grade of adverse events assessed by NCI CTCAE version 5.0 [ Time Frame: Up to 4 years ]
    Will assess incidence and grade of adverse events (clinical manifestations and laboratory tests) with particular attention to >= grade 2 adverse events over time by dose.

  3. Maximum tolerated dose [ Time Frame: Up to 28 days ]
    Defined according to the 3+3 design. Deaths during the study will be documented.


Secondary Outcome Measures :
  1. Dose-limiting toxicity [ Time Frame: Up to 28 days ]
  2. Categorization of response based on Response Evaluation Criteria in Solid Tumors 1.1 [ Time Frame: Up to 4 years ]
    A patient will be determined as having a response if he/she has complete response, partial response or stable disease for at least 4 months; a patient will be determined as a non-response if there is no evidence of response by 4 months during this study.

  3. Minimum detectable effect size [ Time Frame: Baseline up to 28 days post-treatment ]
    Will use the Wilcoxon signed-rank test to calculate the minimum detectable effect size on biomarker data and tumor response. A mixed model accounting for patient effects will be used to analyze longitudinal data (including biomarker data) over time.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients have advanced malignancy (high-grade epithelial ovarian cancer or cancer harboring K-RAS mutation), either refractory to standard therapy or for which no effective standard therapy is available
  • Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 and life expectancy of greater than 3 months and/or other performance status of 0 to 1
  • Female patients who:

    • Are postmenopausal for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of childbearing potential, agree to practice 1 highly effective method of contraception and one additional effective (barrier) method at the same time, from the time of signing the informed consent through 180 days after the last dose of study drug, OR
    • Agree to practice true abstinence, when is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods), withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together)
    • Agree not to donate eggs (ova) during the course of this study or 180 days after receiving their last dose of study drug
  • Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:

    • Agree to practice effective barrier contraception during the entire study treatment period and through 180 days after the last dose of study drug, or
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception. Female and male condoms should not be used together.)
    • Agree not to donate sperm during the course of this study or within 180 days after receiving their last dose of study drug
  • Absolute neutrophil count (ANC) >= 1,500/uL
  • Platelet count >= 100,000/uL (red blood cell count [RBC] and platelet transfusion allowed >= 14 days before assessment)
  • Hemoglobin >= 8 g/dL (RBC and platelet transfusion allowed >= 14 days before assessment)
  • Total bilirubin =< 1.5 x the upper limit of the normal range (ULN) (except patients with Gilbert's syndrome, who must have a total bilirubin =< 3.0 mg/dL)
  • Aminotransferases alanine (ALT) and aspartate (AST) =< 2.5 x ULN or =< 5 x ULN if hepatic metastasis
  • Serum creatinine =< 1 x ULN and creatine clearance >= 60 mL/min either as estimated by the Cockcroft-Gault equation or based on urine collection (12 or 24 hours) if serum creatinine is abnormal
  • Lipase =< 1.5 x ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis
  • Amylase =< 1.5 x ULN with no clinical symptoms suggestive of pancreatitis or cholecystitis
  • Blood pressure =< grade 1 (hypertensive patients are permitted if their blood pressure is controlled to =< grade 1 by hypertensive medications and glycosylated hemoglobin is =< 6.5%)
  • Recovered (=< grade 1 toxicity) from the reversible effects of prior anticancer therapy
  • Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
  • Patients may receive palliative radiation therapy immediately before or during the treatment if the radiation therapy is not delivered to the sole target lesions
  • Patients must be able to take oral medications without medical history of malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the study agents
  • Patients have prior therapy with a taxane
  • Patients agree to provide archival tissue block or 10 formalin-fixed paraffin-embedded (FFPE) slides paraffin for use in pharmacodynamics correlative studies

Exclusion Criteria:

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring intravenous antibiotics, symptomatic congestive heart failure (New York Heart Association [NYHA] Class III or IV), or history of myocardial infarction, unstable angina, stroke or transient ischemic attack within 6 months prior to study enrollment
  • Active brain metastases or leptomeningeal metastases
  • Known hypersensitivity (eg, anaphylactic and anaphylactoid reactions) to any particular combination drug will result in a patient being ineligible for inclusion in that particular cohort
  • History of drug-induced pneumonitis requiring treatment with steroids; history of idiopathic pulmonary fibrosis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted
  • Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day 1 before first dose of study drug
  • Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol
  • Life-threatening illness unrelated to cancer that could, in the investigator's opinion, make the patient not appropriate for this study
  • Known human immunodeficiency virus (HIV) positive
  • Known hepatitis B surface antigen positive, or known or suspected active hepatitis C infection
  • Any treatment specific for systemic tumor control within 3 weeks prior to the initiation of the study drugs; or within 2 weeks if cytotoxic agents were given weekly (within 6 weeks for nitrosoureas or mitomycin C), or within 5 half-lives for targeted agents with half-lives and pharmacodynamic effects lasting less than 4 days (that includes but is not limited to erlotinib, sorafenib, sunitinib, bortezomib, and other similar agents), or failure to recover from toxic effects of any therapy prior to the study drug treatment
  • Any clinically significant comorbidities, such as uncontrolled pulmonary disease, known impaired cardiac function or clinically significant cardiac disease (specified below), active central nervous system (CNS) disease, active infection, or any other condition that could compromise the patient's participation in the study. Patients with any of the following cardiovascular conditions are excluded:

    • Acute myocardial infarction within 6 months before starting study drug
    • Current or history of New York Heart Association Class III or IV heart failure
    • Evidence of current, uncontrolled cardiovascular conditions including cardiac arrhythmias, angina, pulmonary hypertension, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
    • Fridericia corrected QT interval (QTcF) > 450 milliseconds (msec) (men) or > 475 msec (women) on a 12-lead electrocardiogram (ECG) during the screening period
    • Abnormalities on 12-lead ECG including, but not limited to, changes in rhythm and intervals that, in the opinion of the investigator, are considered to be clinically significant
  • Use or consumption of any of the following substances:

    • Medications or supplements that are known to be inhibitors of P-glycoprotein (gp) and/or strong reversible inhibitors of CYP3A within 5 times the inhibitor half-life (if a reasonable half-life estimate is known), or within 7 days (if a reasonable half-life estimate is unknown), before the first dose of study drug. In general, the use of these agents is not permitted during the study except in cases where an adverse event (AE) must be managed
    • Medications or supplements that are known to be strong CYP3A mechanism-based inhibitors or strong CYP3A inducers and/or P-gp inducers within 7 days, or within 5 times the inhibitor or inducer half-life (whichever is longer), before the first dose of study drug. In general, the use of these agents is not permitted during the study except in cases where an AE must be managed
    • Grapefruit-containing food or beverages within 5 days before the first dose of study drug. Note that grapefruit-containing food and beverages are not permitted during the study
  • Major surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery
  • Systemic infection requiring parenteral antibiotic therapy or other serious infection (bacterial, fungal or viral) within 21 days before the first dose of study drug. Patients who are at substantial risk of developing an infection may receive prophylaxis at the study of study treatment per investigator's discretion
  • Active secondary malignancy that requires treatment. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection and are considered disease-free at the time of study entry
  • Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of TAK-659 including difficulty swallowing tablets or diarrhea > grade 1 despite supportive therapy. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
  • Patients with clinical bleeding, active gastric or duodenal ulcer
  • Grade 2 or higher peripheral neuropathy
  • Left ventricular ejection fraction (LVEF) is less than 50% on echocardiography (ECHO) or multiple-gated acquisition (MUGA) scanning or QTc is greater than 450 milliseconds (msec) for men and greater than 475 msec for women at screening
  • Treatment with high-dose corticosteroids for anticancer purposes within 14 days before the first dose of TAK-659; daily dose equivalent to 10 mg oral prednisone or less is permitted. Corticosteroids for topical use or in nasal spray or inhalers, or for premedication for paclitaxel are allowed
  • Lack of suitable venous access for the study-required blood sampling
  • Grade 1 or higher ophthalmologic disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03756818


Contacts
Contact: Siqing Fu 713-563-0181 siqingfu@mdanderson.org

Locations
United States, Texas
M D Anderson Cancer Center Not yet recruiting
Houston, Texas, United States, 77030
Contact: Siqing Fu    713-563-0181      
Principal Investigator: Siqing Fu         
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Principal Investigator: Siqing Fu M.D. Anderson Cancer Center

Additional Information:
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT03756818     History of Changes
Other Study ID Numbers: 2017-0422
NCI-2018-02665 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2017-0422 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
First Posted: November 28, 2018    Key Record Dates
Last Update Posted: November 28, 2018
Last Verified: November 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Carcinoma
Neoplasms
Ovarian Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Paclitaxel
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action